Clinical Testing News and Research

RSS

Bionovo to present phase 1B trial results of BZL101 in metastatic breast cancer

Bionovo, Inc. has announced the company will present results from the Phase 1B clinical trial of their lead drug candidate for advanced metastatic breast cancer, BZL101, at the Society for Integrative Oncology's Fifth International Conference in Atlanta, Georgia.

20 Nov 2008

KAI Pharmaceuticals reports positive results for KAI-1678 in pain reduction

KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced preclinical results demonstrating the effectiveness of KAI-1678 in reversing pain (hyperalgesia and allodynia) in multiple preclinical models.

19 Nov 2008

Systems biology brings hope of speeding up drug development

Almost every day brings news of an apparent breakthrough against cancer, infectious diseases, or metabolic conditions like diabetes, but these rarely translate into effective therapies or drugs, and even if they do clinical development usually takes well over a decade.

19 Nov 2008

BioCis Pharma starts phase IIa clinical testing of ProtoCure in atopic dermatitis

BioCis Pharma Ltd a privately-held drug development company with its headquarters in Turku, Finland, announced that it has begun Phase IIa clinical testing of ProtoCure(TM) emulsion cream, the company's novel topical drug for dermatology.

7 Nov 2008

Simple gene-based blood test, quicker, more accurate evaluation for cystic fibrosis

Researchers at National Jewish Health have identified a simple gene-based blood test that more accurately and quickly measures cystic fibrosis patients' response to therapy than current tests.

26 Oct 2008

FDA grants orphan drug status to Reata's pancreatic cancer drug

Reata Pharmaceuticals, Inc. has announced that RTA 402 has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer. RTA 402 is currently being studied in a Phase 1/2 trial in patients with pancreatic cancer, and is also in Phase 2 development for chronic kidney disease.

16 Oct 2008

Existing anti-obesity drugs may be effective against flu, hepatitis and HIV

Viruses dramatically increase cellular metabolism, and existing anti-obesity drugs may represent a new way to block these metabolic changes and inhibit viral infection, according to a study published today in the journal Nature Biotechnology.

29 Sep 2008

Bill & Melinda Gates Foundation to provide $168.7 million for malaria vaccine research

Bill Gates announced today that the Bill & Melinda Gates Foundation will provide $168.7 million to PATH for its Malaria Vaccine Initiative to develop vaccines for malaria -- a disease that kills thousands of African children every day.

25 Sep 2008

Concert Pharmaceuticals initiates CTP-347 phase I clinical trial

Concert Pharmaceuticals, Inc. announced today that it has initiated a Phase I study in healthy volunteers to evaluate the safety, tolerability and pharmacokinetics of CTP-347, a novel deuterium-containing serotonin modulator created by Concert researchers.

25 Sep 2008

GlaxoSmithKline and Cellzome announce major strategic alliance

Cellzome Inc. and GlaxoSmithKline have announced the signing of a worldwide strategic alliance to discover, develop and market novel kinase-targeted therapeutics to treat inflammatory diseases.

10 Sep 2008

Coated lenses set to reduce 'post-op' infections for cataract patients

Research presented at the British Pharmaceutical Conference (BPC) in Manchester reveals that coating an artificial lens with antibiotics could significantly reduce the risk of post-operative infection, and even blindness, for cataract patients.

7 Sep 2008

AFFiRiS GmbH alzheimer's vaccine progress

In the clinical phase I trial AFF001, AFFiRiS GmbH has now recruited the 24 Alzheimer patients planned for this trial. The trial aims to investigate the tolerability and safety of an innovative Alzheimer's vaccine (AFFITOPE AD01).

16 Jul 2008

Natural substance Argyrin shows promise for new cancer therapies

The effective treatment of many forms of cancer continues to pose a major problem for medicine. Many tumours fail to respond to standard forms of chemotherapy or become resistant to the medication.

8 Jul 2008

Growth-stimulating molecule called p110beta a promising cancer drug target in prostate tumors

Scientists at Dana-Farber Cancer Institute report they have blocked the development of prostate tumors in cancer-prone mice by knocking out a molecular unit they describe as a "powerhouse" that drives runaway cell growth.

27 Jun 2008

Industry supports international melanoma research

Provectus Pharmaceuticals and the Australia and New Zealand Melanoma Trials Group (ANZMTG) have joined forces to advance cutting edge melanoma research at the University of Sydney.

15 Jun 2008

Spectral Modeling technology substantiated through creation of antipsychotic bank of drug candidates

LIUS Molecular Design is pleased to announce that it has successfully created two antipsychotic drug candidates with third party confirmation of predicted biological activities via in vitro testing.

19 May 2008

Researchers find way to make tumor cells more sensitive to hyperthermia-enhanced radiation therapy

Tumors have a unique vulnerability that can be exploited to make them more sensitive to heat and radiation, researchers at Washington University School of Medicine in St. Louis report.

6 May 2008

Novavax opens new U.S. vaccine plant in Rockville, Maryland

Officials from Novavax, Inc., the State of Maryland and Montgomery County today celebrated the opening of Novavax's new state-of-the-art vaccine production facility at the company's headquarters in Rockville, Maryland.

1 May 2008

Scientists determine drug target for the most potent botulinum neurotoxin

Botulinum neurotoxin - responsible for the deadly food poisoning disease botulism and for the beneficial effects of smoothing out facial wrinkles - can also be used as a dreaded biological weapon. When ingested or inhaled, less than a billionth of an ounce can cause muscle paralysis and eventual death. Although experimental vaccines administered prior to exposure can inhibit the destructive action of this neurotoxin - the most deadly protein known to humans - no effective pharmacological treatment exists.

29 Apr 2008